Journal of Shandong University (Health Sciences) ›› 2020, Vol. 58 ›› Issue (1): 60-66.doi: 10.6040/j.issn.1671-7554.0.2019.1166

Previous Articles    

Antiretrovial treatment effect and related factors of patients with human immunodeficiency virus infection and hepatitis B virus co-infection in Shandong Province

LIU Cuixiao1, ZHU Xiaoyan2, ZHANG Na2, HUANG Pengxiang2, WANG Guoyong2, KANG Dianmin1,2,3   

  1. 1. Department of Epidemiology, School of Public Health, Shandong University, Jinan 250012, Shandong, China;
    2. Division of AIDS Control and Prevention, Shandong Center for Disease Control and Prevention, Jinan 250014, Shandong, China;
    3. Key Laboratory of Prevention and Control of Infections Diseases in Shandong Province, Jinan 250014, Shandong, China
  • Published:2022-09-27

PDF (PC)

8

Abstract: Objective To investigate the treatment effect and its related factors among human immunodeficiency virus(HIV)/ acquired immunodeficiency syndrome(AIDS)patients with or without HBV co-infection in Shandong Province. Methods Data of 500 HIV/AIDS patients were collected from the Shandong AIDS Antiviral Treatment Database during 2015 and 2017. The patients were divided into the HIV infection group(n=168)and the HIV/HBV co-infection group(n=332), aged(35.41±10.24)and(34.75±9.22)years, respectively. The basic situation of patients were analyzed, and the changes of related indicators after treatment for 12 months were compared. Logistic regression model was used to analyze the related factors of the antiretroviral therapy effect. Results Most of patients were male, unmarried, 山 东 大 学 学 报 (医 学 版)58卷1期 -刘翠晓,等.山东省单纯艾滋病病毒感染与合并乙型肝炎病毒感染者抗病毒治疗效果及相关因素 \=-and infected by sexual transmission. After treatment for 12 months, the median of CD4+ T lymphocyte increased from 315.5/μL to 439.0/μL in HIV infection group, and from 349.5/μL to 491.0/μL in HIV/HBV co-infection group. The proportion of immunological failure was 16.3% in the HIV infection group and 44.6% in the HIV/HBV co-infection group. The proportion of virological failure was 7.5% in the HIV infection group and 13.1% in the HIV/HBV co-infection group. Multivariate Logistic analysis of treatment outcomes showed that immunological failure was associated with HBV co-infection(OR=1.619, 95%CI: 1.061-2.469), 35-44 years old (OR=2.695, 95%CI: 1.145-6.345)and older than 45 years old (OR=3.101, 95%CI: 1.291-7.450). The occurrence of virological failure was associated with HBV co-infection(OR=2.156, 95%CI: 1.142-4.070)and clinical stage III or IV (OR=2.443, 95%CI: 1.102-5.416). Conclusion The treatment effect of patients with HIV/HBV co-infection is not as good as that with HIV simple infection. Screening and effective management of HBV in HIV/AIDS patients should be strengthened. Choosing the suitable treatment drug for different people is crucial and can improve the effectiveness of antiviral treatment.

Key words: Hepatitis B virus, Human immunodeficiency virus, Co-infection, Antiretroviral therapy

CLC Number: 

  • R512.91
[1] Xie J, Han Y, Qiu Z, et al. Prevalence of hepatitis B and C viruses in HIV-positive patients in China: a cross-sectional study[J]. J Int AIDS Soc, 2016, 19(1): 20659. doi: 10.7448/IAS.19.1.20659.
[2] Sun HY, Sheng WH, Tsai MS, et al. Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review[J]. World J Gastroenterol, 2014, 20(40): 14598-14614.
[3] Adekunle AE, Oladimeji AA, Temi AP, et al. Baseline CD4+ T lymphocyte cell counts, hepatitis B and C viruses seropositivity in adults with Human Immunodeficiency Virus infection at a tertiary hospital in Nigeria[J]. Pan Afr Med J, 2011, 9: 6.
[4] Easterbrook P, Sands A, Harmanci H. Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited sett-ings[J]. Semin Liver Dis, 2012, 32(2): 147-157.
[5] Kourtis AP, Bulterys M, Hu DJ, et al. HIV-HBV coinfection—a global challenge [J]. N Engl J Med, 2012, 366(19): 1749-1752.
[6] Prussing C, Chan C, Pinchoff J, et al. HIV and viral hepatitis co-infection in New York City, 2000-2010: prevalence and case characteristics[J]. Epidemiol Infect, 2015, 143(7): 1408-1416.
[7] 赵燕. HIV感染者个案管理实用手册[M]. 北京: 人民卫生出版社, 2018.
[8] 中华医学会感染学分会艾滋病丙型肝炎学组. 中国艾滋病诊疗指南(2018版)[J]. 新发传染病电子杂志, 2019, 4(2): 65-84. Chinese Medical Association Infectious Diseases Branch AIDS Hepatitis C Professional Group. Chinese guidelines for diagnosis and treatment of HIV/AIDS(2018)[J]. Electronic Journal of Emerging Infectious Diseases, 2019, 4(2): 65-84.
[9] Van Griensven J, Phirum L, Choun K, et al. Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia[J]. PLoS One, 2014, 9(2): e88552. doi: 10.1371/journal.pone.0088552.
[10] Zhang F, Zhu H, Wu Y, et al. HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010-12: a retrospective observational cohort study[J]. Lancet Infect Dis, 2014, 14(11): 1065-1072.
[11] 杨兴光, 钱跃升, 张娜, 等. 山东省艾滋病流行特征分析[J]. 中国病原生物学杂志, 2018, 13(1): 68-71. YANG Xingguang, QIAN Yuesheng, ZHANG Na, et al. Analysis of the epidemiological characteristics of HIV/AIDS in Shandong Province[J]. Journal of Pathogen Biology, 2018, 13(1): 68-71.
[12] 胡庆玲, 谢元林. 人类免疫缺陷病毒合并乙型肝炎病毒感染患者高效抗反转录病毒治疗效果和肝脏损伤研究[J]. 广东医学, 2017, 38(7): 1029-1031. HU Qingling, XIE Yuanlin. Response and liver injury of highly active antiretroviral therapy on human immunodeficiency virus co-infection[J]. Guangdong Medical Journal, 2017, 38(7): 1029-1031.
[13] 汪明勋. 对艾滋病合并HBV感染患者进行高效抗逆转录病毒治疗的效果研究[J]. 当代医药论丛, 2018, 16(22): 8-9. WANG Mingxun. Effect of highly effective antiretroviral therapy for the patients of HIV with HBV[J]. Contemporary Medical Symposium, 2018, 16(22): 8-9.
[14] Sheng WH, Chen MY, Hsieh SM, et al. Impact of chronic hepatitis B virus(HBV)infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic[J]. Clin Infect Dis, 2004, 38(10): 1471-1477.
[15] Su S, Fairley CK, Sasadeusz J, et al. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: regimen selection, hepatotoxicity, and antiretroviral therapy outcome[J]. J Med Virol, 2017, 90(3): 518-525.
[16] Zhu J, Yang W, Feng Y, et al. Treatment effects of the differential first-line antiretroviral regimens among HIV/HBV coinfected patients in southwest China: an observational study[J]. Sci Rep, 2019, 9(1): 1006. doi: 10.1038/s41598-018-37148-8.
[17] Chen M, Wong WW, Law MG, et al. Hepatitis B and C co-infection in HIV patients from the TREAT Asia HIV Observational Database: analysis of risk factors and survival[J]. PLoS One, 2016, 11(3): e0150512. doi: 10.1371/journal.pone.0150512.
[18] 毛霖, 李武, 汪习成. HIV/HBV合并感染研究进展[J]. 传染病信息, 2014, 27(2): 126-128. MAO Lin, LI Wu, WANG Xicheng. Research progress of HIV/HBV co-infection[J]. Infectious Disease Information, 2014, 27(2): 126-128.
[19] Wandeler G, Gsponer T, Bihl F, et al. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study[J]. J Infect Dis, 2013, 208(9): 1454-1458.
[20] 聂源, 兰芸, 李锋, 等. HBeAg状态对HIV/HBV合并感染者免疫重建的影响[J]. 国际流行病学传染病学杂志, 2018, 45(5): 293-296. NIE Yuan, LAN Yun, LI Feng, et al. Impact of HBeAg status on immune reconstitution in HIV/HBV co-infected patients[J]. International Journal of Epidemiology and Infectious Disease, 2018, 45(5): 293-296.
[21] 郑武, 笪琴, 张薇, 等. 湖北省接受艾滋病HAART患者CD4+T淋巴细胞变化趋势及影响因素[J]. 实用预防医学, 2018, 25(11): 1325-1328. ZHENG Wu, DA Qin, ZHANG Wei, et al. Changing trend of CD4+T lymphocyte count and its influencing factors in HIV/AIDS patients with HAART in Hubei Province[J]. Practical Preventive Medicine, 2018, 25(11): 1325-1328.
[22] 粟斌, 夏炜, 姜太一, 等. 老年HIV感染群体的扩大已呈不容低估的发展趋势[J]. 中国艾滋病性病, 2019, 25(2): 201-203. SU Bin, XIA Wei, JIANG Taiyi, et al. Expansion of the elderly HIV infection group—a trend to be never underestimated[J]. Chinese Journal of AIDS & STD, 2019, 25(2): 201-203.
[23] 陈国春, 卫峥, 马波, 等. 艾滋病患者高效抗病毒治疗后免疫重建及预后影响因素研究[J]. 中华医院感染学杂志, 2018, 28(22): 3414-3417, 3421. CHEN Guochun, WEI Zheng, MA Bo, et al. Influencing factors for immune reconstruction and prognosis of AIDS patients after highly active antiretroviral therapy[J]. Chinese Journal of Nosocomiology, 2018, 28(22): 3414-3417, 3421.
[1] Yuchen FAN. Current progress on prevention of mother to child transmission of hepatitis B virus [J]. Journal of Shandong University (Health Sciences), 2021, 59(5): 46-51,67.
[2] BI Tao, LU Qianqian, SUN Chuandong. Effects of adenouvirus-mediated HBx on lymphocyte in vitro [J]. Journal of Shandong University (Health Sciences), 2018, 56(7): 15-20.
[3] YUAN Yuan, SI Heng, LIU Hongwei, LIU Chunhua, WANG Zhe, RUAN Yuhua, XING Hui. HIV drug resistance and the impact of antiretroviral therapy initiated at different stages among AIDS patiens [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(9): 77-81.
[4] WANG Hao, ZHANG Na, XUE Fuzhong, WANG Ping, KANG Dianmin, LIU Yanxun. Spatial epidemiological characteristics of HIV infections and AIDS patients in Shandong Province [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(2): 81-86.
[5] FU Xiao-li， WANG Lei， LIU Feng. HBsAg quantitative value in different stages of hepatitis B virus infection and its correlations with serum HBV DNA and age [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(5): 94-98.
[6] XU Hui1, WANG Yi-guo2, LIU Chang-hong2, LIU Qian2, DU Juan3. Expression of HBV and its effects on the transdifferentiation in HK-2 cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(3): 15-20.
[7] SHI Xiao-lin1, KANG Dian-min2, HUANG Peng-xiang2, LIAO Mei-zhen2, TAO Xiao-run2, WANG Guo-yong2, SU Sheng-li2, WANG Zhen-hong3. Community-based survey on syphilis prevalence and associated factors among ATS users in Shandong Province [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(12): 107-110.
[8] LIU Jin-rong1， WANG-Lei2， DU Wen-jun3， ZHEN Jun-hui4. Expression of IgG subclasses and its significance in hepatitis B
virus associated membranous nephropathy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(10): 111-114.
[9] HONG Sen1， WANG Yi-guo2， LIU Chang-hong2， ZHANG Peng-ju3， LIU Qian2. Expression of recombinant HBV in the NHMC cells and its influence on cell apoptosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(1): 34-.
[10] FAN Chun-guang1, WANG Chun-mei2, WANG Yan1, LI Li1, SUN Wen-sheng3, LIU Yu-gang1, LI Rui-feng1. Construction of an miR-122 expression vector and its inhibitory effects on proliferation of HepG2.2.15 cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(10): 118-.
[11] TIAN Ming-zhong1 ，GAO Jie1， WANG Dong-qiu1， ZHU Chang-jun2. Gene therapy of endoribonucleaseⅢ-prepared siRNAs (esiRNA) library for HBV infection [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(7): 42-46.
[12] GUAN Yan-yan1, YAO Yong-yuan1, WANG Gang1, SHAO Li-hua2, SAI Lin-tao1, MA Li-xian1. Influences of DMSO and dexamethasone on  HBV infection in HepCHLine4  cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(10): 65-.
[13] XUE Yan1，　WANG Lei1，　XU Wansu2
.

Domestic fluorescence quantitative PCR reagents and COBAS Amplicor assay in measuring HBVDNA: a comparison study

[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(04): 62-64.
[14] LIU You-de,WANG Lei,ZHOU Pei-jing,ZHUANG Hui. Proportional changes of HBeAg negative chronic hepatitis B and liver cirrhosis B and the HBV genotype in Shandong Province [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(1): 94-96.
[15] ZHU Ming-ming,SUN Cheng-gang,LIU Xiao-hua,YANG Ai-xin,SUN Dan. Genetic polymorphisms of CYP17 and risks of cirrhosis or hepatocellular carcinoma in hepatitis B-infected patients [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(1): 76-79.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd